Results 51 to 60 of about 507,873 (296)

To respond or not to respond - a personal perspective of intestinal tolerance [PDF]

, 2018
For many years, the intestine was one of the poor relations of the immunology world, being a realm inhabited mostly by specialists and those interested in unusual phenomena.
A Besredka, A Goubier, A Iwasaki, A Konrad, A Limmer, A Mortha, A Vaillant, AJ MacPherson, Allan McI. Mowat, AM Mowat, B Cassani, B Dubois, B Jabri, B Johansson-Lindbom, C Asseman, C Berlin, C Siewert, C Varol, CC Bain, CC Bain, CL Scott, CL Scott, CM Sun, CR Mackay, CR Stokes, D Esterhazy, D Fina, D Mucida, D Sichien, DP McGovern, DS Shouval, E Jaensson, E Jaensson-Gyllenback, E Mazzini, E Zigmond, EJ Kunkel, EM Nilsen, EM Nilsen, F Broere, F Ginhoux, F Hauet-Broere, F Powrie, FG Chirdo, G Lack, G Matteoli, G Mayrhofer, G Monteleone, GG MacPherson, H Arentz-Hanson, H Fukaura, H Tlaskalova, HG Wells, HL Klaasen, HL Weiner, HL Weiner, I Vicente-Suarez, ID Iliev, II Ivanov, J Farache, J Farache, JA Mattingly, JA Mattingly, JB Sun, JF Heremans, JH Niess, JL Coombes, JL Gowans, JL Viney, JM Blander, JP Hugot, JR Battisto, JR McDole, K Atarashi, K Atarashi, K Lahl, K Nagatani, K Takeda, KG McDonald, KM Luda, KM Smith, KP Zimmer, KS Kim, L Maiuri, L Maiuri, L Saurer, LA Hanson, LA Reynolds, LA Waaij van der, LM Sollid, M Boucard-Jourdin, M Butler, M Chieppa, M Karlsson, M Murai, M Rescigno, M Rimoldi, M Tsuji, M Yoshida, MH Jang, MH Jang, MO Li, MR Hepworth, MR Karlsson, MW Chase, N Korneychuk, N Satoh-Takayama, N Sudo, O Schulz, P Brandtzaeg, P Morrissey, PA Crabbe, PB Carter, PM Smith, R Bouziat, R Kuhn, R Zeng, R Zeng, RE Araya, RL Owen, RW DePaolo, S Hue, S Husby, S Husby, S Kawamoto, S Strobel, S Strobel, S Veenbergen, S Wilks, SI Hammerschmidt, SK Mazmanian, SV Kim, T Joeris, T Worbs, TB Tomasi Jr, TL Denning, U Hadis, V Cerovic, V Gaboriau-Routhiau, Y Chen, Y Cong, Y Ogura, ZM Falchuk, Ø Molberg   +142 more
core   +1 more source

Tolerating Factor VIII: Recent Progress

Frontiers in Immunology, 2020
Development of neutralizing antibodies against biotherapeutic agents administered to prevent or treat various clinical conditions is a longstanding and growing problem faced by patients, medical providers and pharmaceutical companies.
Sebastien Lacroix-Desmazes, Jan Voorberg, David Lillicrap, David W. Scott, Kathleen P. Pratt   +4 more
doaj   +1 more source

Growth of donor-derived dendritic cells from the bone marrow of murine liver auograft recipients in response to granulocyte/macrophage colony-stimulating factor [PDF]

, 1995
Allografts of the liver, which has a comparatively heavy leukocyte content compared with other vascularized organs, are accepted permanently across major histocompatibility complex barriers in many murine strain combinations without immunosuppressive ...
Fu, F, Fung, JJ, Lu, L, McCaslin, D, Qian, S, Rao, AS, Rudert, WA, Starzl, TE, Thomson, AW, Trucco, M   +9 more
core   +1 more source

Cytokines and Peripheral Tolerance to Alloantigen

Immunological Reviews, 1993
The induction of peripheral tolerance to alloantigen is accompanied in many cases by a decrease in the production of cytokines such as IL-2 and IFN gamma, yet a sustained production of cytokines such as IL-10 and IL-4. Whether or not this altered pattern of cytokine production in tolerant animals is causally related to the induction and/or maintenance ...
Dallman, M, Wood, K, Hamano, K, Bushell, A, Morris, P, Wood, M, Charlton, H   +6 more
openaire   +4 more sources

Clinical Insights Into Hypercalcemia of Malignancy in Childhood

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Hypercalcemia of malignancy (HCM) is a rare but life‐threatening metabolic emergency in children that occurs in less than 1% of pediatric cancer cases, with a reported incidence ranging from 0.4% to 1.0% across different studies. While it is observed in 10%–20% of adult malignancies, pediatric HCM remains relatively uncommon.
Hüseyin Anıl Korkmaz
wiley   +1 more source

Circadian and Metabolic Effects of Light: Implications in Weight Homeostasis and Health [PDF]

, 2017
Daily interactions between the hypothalamic circadian clock at the suprachiasmatic nucleus (SCN) and peripheral circadian oscillators regulate physiology and metabolism to set temporal variations in homeostatic regulation.
Diego A. Golombek, Juan J. Chiesa, Leandro P. Casiraghi, Natalia Paladino, Paula García Moro, Santiago A. Plano, Santiago A. Plano   +6 more
core   +2 more sources

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács, Zoltán Köllő, Balázs Gellért Karvaly, Mahmoud Obeidat, Rita Nagy, Péter Hegyi, Brigitta Teutsch, Eszter Tuboly, Miklós Garami   +8 more
wiley   +1 more source

Sirolimus for Extracranial Arteriovenous Malformations: A Scoping Review of the Evidence in Syndromic and Non‐Syndromic Cases

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Arteriovenous malformations (AVMs) are rare, high‐flow, vascular anomalies that can occur either sporadically or as part of a genetic syndrome. AVMs can progress with serious morbidity and even mortality if left unchecked. Sirolimus is an mTOR inhibitor that is effective in low‐flow vascular malformations; however, its role in AVMs is unclear.
Will Swansson, Ingrid Winship, Gary Hammerschlag, Laura Scardamaglia   +3 more
wiley   +1 more source

Intravitreal GD2‐Specific Chimeric Antigen Receptor T‐Cell Therapy for Refractory Retinoblastoma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Effective treatments for advanced, treatment‐resistant retinoblastoma (RB) remain limited. GD2‐specific chimeric antigen receptor (CAR) T cells show potent antitumor activity with minimal toxicity but have not previously been evaluated in RB.
Subongkoch Subhadhirasakul, Jatuporn Sujjitjoon, Pa‐thai Yenchitsomanus, Kridtin Jarutatsanangkoon, Ng Wei Loon, Kleebsabai Sanpakit, Jassada Buaboonnam, Chayamon Takpradit, Pornpimon Yuti, Nunghathai Sawasdee, Piriya Luangwattananun, Siripakorn Sangkitporn, Arnan Limmahachai, La‐ongsri Atchaneeyasakul   +13 more
wiley   +1 more source

Revisiting T Cell Tolerance as a Checkpoint Target for Cancer Immunotherapy

Frontiers in Immunology, 2020
Immunotherapy has revolutionized the treatment of cancer. Nevertheless, the majority of patients do not respond to therapy, meaning a deeper understanding of tumor immune evasion strategies is required to boost treatment efficacy.
Simone Nüssing, Simone Nüssing, Joseph A. Trapani, Joseph A. Trapani, Ian A. Parish, Ian A. Parish   +5 more
doaj   +1 more source